{"schema":"https://ver.cy/schemas/card/1.0.0","id":"vr.tr.inamrinone","code":"thing-q422724","url":"https://ver.cy/models/thing/q422724/","name":"inamrinone","alternateNames":[],"kind":"thing","status":"published","version":"0.1.0-research.1","language":"en","classifiers":{"family":"Thing Registry","category":"Physical world and living systems","entryKind":"thing","plane":"PHY","domain":["PHY.MAT"],"industry":[],"navPath":"","tags":[],"facets":{}},"whatItIs":"Inamrinone, formerly called amrinone, is a synthetic bipyridine phosphodiesterase type 3 inhibitor that increases myocardial contractility and causes vasodilation, used intravenously for short-term management of heart failure.","purpose":"Enable an AI agent to recognise inamrinone, assess the identity and condition of a specific material, and determine which handling, formulation or research actions its evidence supports.","scope":{"in":["Chemical identity, including the relationship between the names inamrinone and amrinone","Distinction between the parent substance, salts, solutions and formulated products","Sample composition, grade, impurities and analytical identity evidence","Physical state, solubility and stability under recorded conditions","Substance-level pharmacological activity, hazards and restrictions"],"out":["Finished injectable products, their excipients, packaging and release specifications","Patient-specific prescribing, dosing and treatment monitoring","Heart failure and other diseases as independently modelled conditions","Manufacturing processes, equipment and facility qualification","Milrinone and other related compounds as separate substances"],"boundaries":[]},"distinguishingFeatures":["Require a verified molecular structure to connect an inamrinone label to the registered substance; a pharmacological class label alone is insufficient.","Resolve amrinone as a potential alternative name using an authoritative identity source rather than treating the spelling difference as evidence of a separate compound.","Distinguish inamrinone from milrinone through structural and analytical evidence rather than similar names or intended effects.","Determine whether an identifier refers to the parent molecule, a salt or a formulated solution before matching the material to the registry entry.","Distinguish chemically identified inamrinone from material qualified for pharmaceutical use through separate purity, impurity and grade evidence."],"structure":{"bundles":[{"id":"inamrinone-identity","name":"Inamrinone identity and naming","description":"Establishes which chemical entity the registry entry denotes and how alternative names resolve to it.","layers":[{"id":"structure-and-identifiers","name":"Structure and identifiers","description":"Anchors recognition in a verified structure and identifiers that refer to the same entity.","findings":[{"id":"identity-anchor","name":"Chemical identity anchor","description":"Record the evidence needed to establish the molecular identity before accepting a label or database match.","questions":[{"text":"Which authoritative structure, molecular formula and CAS, PubChem or EC identifiers refer specifically to parent inamrinone?","id":"identity-anchor-q01","kind":"definition"},{"text":"Does each identifier resolve to that same entity, or does any refer to a salt, mixture or product?","id":"identity-anchor-q02","kind":"boundary"}]}]},{"id":"alternative-names-and-neighbours","name":"Alternative names and neighbouring compounds","description":"Resolves historical terminology and prevents confusion with milrinone or other related substances.","findings":[{"id":"name-resolution","name":"Evidence-backed name resolution","description":"Treat name equivalence and separation from similarly named compounds as explicit identity decisions.","questions":[{"text":"Which authoritative records establish the relationship between amrinone and inamrinone, and in what naming context?","id":"name-resolution-q01","kind":"provenance"},{"text":"Which structural or analytical discriminants separate inamrinone from milrinone when labels or records are ambiguous?","id":"name-resolution-q02","kind":"measurement"}]}]}]},{"id":"material-form-and-quality","name":"Material form and quality","description":"Describes what a specific inamrinone material contains and the evidence supporting its grade.","layers":[{"id":"form-and-composition","name":"Form and composition","description":"Separates the parent substance from counterions, water, solvents and formulation components.","findings":[{"id":"parent-equivalent-composition","name":"Composition and parent-equivalent basis","description":"Establish the material form before interpreting mass, assay or solution concentration.","questions":[{"text":"Is this material parent inamrinone, a characterised salt or a solution containing additional components?","id":"parent-equivalent-composition-q01","kind":"definition"},{"text":"What composition evidence supports converting its reported mass or concentration to an inamrinone parent-equivalent quantity?","id":"parent-equivalent-composition-q02","kind":"measurement"}]}]},{"id":"identity-assay-and-impurities","name":"Identity, assay and impurities","description":"Connects sample qualification to analytical methods and applicable acceptance criteria.","findings":[{"id":"analytical-qualification","name":"Analytical qualification","description":"Record identity confirmation, assay and impurities independently of the supplier's grade label.","questions":[{"text":"Which methods and reference standards confirm inamrinone identity and quantify its assay in this material form?","id":"analytical-qualification-q01","kind":"measurement"},{"text":"Which impurity limits and grade requirements apply to the intended use, and does the lot-specific evidence meet them?","id":"analytical-qualification-q02","kind":"action"}]}]}]},{"id":"physical-behaviour-and-stability","name":"Physical behaviour and stability","description":"Captures condition-dependent behaviour relevant to storing, dissolving and assessing inamrinone.","layers":[{"id":"solid-and-solution-behaviour","name":"Solid and solution behaviour","description":"Records thermal behaviour and dissolution evidence without transferring values between forms.","findings":[{"id":"conditioned-physical-properties","name":"Conditioned physical properties","description":"Associate physical measurements with form, pH, solvent and temperature.","questions":[{"text":"What measured solubility and acid-base behaviour are reported for verified inamrinone forms at specified pH and temperature?","id":"conditioned-physical-properties-q01","kind":"measurement"},{"text":"Which thermal observations describe melting or decomposition, and is a reported boiling point experimentally supported or merely estimated?","id":"conditioned-physical-properties-q02","kind":"provenance"}]}]},{"id":"degradation-and-compatibility","name":"Degradation and compatibility","description":"Relates environmental exposure and solution conditions to chemical or physical deterioration.","findings":[{"id":"evidenced-stability-envelope","name":"Evidenced stability limits","description":"Define supported storage and preparation conditions using stability-indicating evidence.","questions":[{"text":"What studies establish the effects of time, temperature, light, moisture and solution pH on inamrinone stability?","id":"evidenced-stability-envelope-q01","kind":"provenance"},{"text":"What analytical or physical evidence requires a stored material or prepared solution to be quarantined, retested or rejected?","id":"evidenced-stability-envelope-q02","kind":"action"}]}]}]},{"id":"pharmacological-evidence","name":"Pharmacological evidence and interpretation","description":"Links inamrinone to experimentally supported target activity and functional effects.","layers":[{"id":"target-activity","name":"Target activity","description":"Examines evidence for phosphodiesterase-related activity and its experimental limits.","findings":[{"id":"pde-activity-evidence","name":"Phosphodiesterase activity evidence","description":"Record the assays needed to establish activity, potency and selectivity attributed to inamrinone.","questions":[{"text":"Which primary studies establish inamrinone activity against PDE3, and which enzyme preparations or isoforms were tested?","id":"pde-activity-evidence-q01","kind":"provenance"},{"text":"What potency and selectivity measurements are available, with units, assay conditions and uncertainty?","id":"pde-activity-evidence-q02","kind":"measurement"}]}]},{"id":"functional-effects-and-transfer","name":"Functional effects and transfer limits","description":"Separates molecular activity, experimental physiological effects and clinical interpretation.","findings":[{"id":"effect-context","name":"Effect in experimental context","description":"Keep reported cardiac and vascular effects attached to their experimental systems and exposures.","questions":[{"text":"Which studies support cardiac contractility or vascular effects attributed to inamrinone, and at what measured exposure?","id":"effect-context-q01","kind":"provenance"},{"text":"Which interpretations require a separate medicinal-product or patient model because substance-level evidence is insufficient?","id":"effect-context-q02","kind":"boundary"}]}]}]},{"id":"hazards-and-use-constraints","name":"Hazards and use constraints","description":"Connects handling and use decisions to evidence for the identified inamrinone material.","layers":[{"id":"handling-hazards","name":"Handling hazards","description":"Establishes applicable hazard information for the substance's supplied form and exposure routes.","findings":[{"id":"material-specific-hazard-evidence","name":"Material-specific hazard evidence","description":"Evaluate safety documentation against the actual identity, concentration and physical form.","questions":[{"text":"What current safety data sheets or authoritative classifications apply to this inamrinone form, including any GHS classification and exposure limits?","id":"material-specific-hazard-evidence-q01","kind":"provenance"},{"text":"Which containment, protective equipment and disposal measures follow from that evidence and the proposed handling operation?","id":"material-specific-hazard-evidence-q02","kind":"action"}]}]},{"id":"qualification-and-regulatory-boundaries","name":"Qualification and regulatory boundaries","description":"Records the jurisdiction, date and object to which a use restriction or authorisation applies.","findings":[{"id":"permitted-use-evidence","name":"Permitted-use evidence","description":"Keep substance qualification distinct from authorisation of an inamrinone-containing product.","questions":[{"text":"Which restrictions or qualification requirements apply to acquiring, researching or supplying this material in the relevant jurisdiction?","id":"permitted-use-evidence-q01","kind":"action"},{"text":"Does each regulatory statement concern inamrinone itself, a particular finished product or a clinical use, and when was it verified?","id":"permitted-use-evidence-q02","kind":"boundary"}]}]}]},{"id":"evidence-and-external-alignment","name":"Evidence and external alignment","description":"What the world already says about this thing, gathered so the model can be checked against it.","layers":[{"id":"reported-evidence","name":"Reported evidence","description":"Findings from the breadth pass, kept separate from the structural claims.","findings":[{"id":"evidence-confidence-notes","name":"Check these first","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these check these first hold for the sense of inamrinone this model covers, and on what evidence?","id":"evidence-confidence-notes-q01","kind":"provenance"}]},{"id":"evidence-identifiers","name":"Identifiers and schemes","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these identifiers and schemes hold for the sense of inamrinone this model covers, and on what evidence?","id":"evidence-identifiers-q01","kind":"provenance"}]},{"id":"evidence-real-world-use","name":"Real-world use","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these real-world use hold for the sense of inamrinone this model covers, and on what evidence?","id":"evidence-real-world-use-q01","kind":"provenance"}]},{"id":"evidence-measurements","name":"Typical measurements","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these typical measurements hold for the sense of inamrinone this model covers, and on what evidence?","id":"evidence-measurements-q01","kind":"provenance"}]},{"id":"evidence-failure-modes-and-hazards","name":"Failure modes and hazards","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these failure modes and hazards hold for the sense of inamrinone this model covers, and on what evidence?","id":"evidence-failure-modes-and-hazards-q01","kind":"provenance"}]},{"id":"evidence-regional-variation","name":"Regional variation","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these regional variation hold for the sense of inamrinone this model covers, and on what evidence?","id":"evidence-regional-variation-q01","kind":"provenance"}]},{"id":"evidence-neighbours","name":"Neighbouring kinds and how to tell them apart","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these neighbouring kinds and how to tell them apart hold for the sense of inamrinone this model covers, and on what evidence?","id":"evidence-neighbours-q01","kind":"provenance"}]}]}]}]},"agentConduct":{"may":["Describe inamrinone's mechanism and its short-term intravenous use in heart failure.","Support clinical teams with monitoring records they have authorised."],"mustNot":["Recommend, dose or adjust an infusion for a patient without a clinician's decision.","Advise its use outside the hospital or as long-term treatment.","Ignore falling platelet counts or arrhythmias reported during treatment."],"requiresHuman":["Starting, stopping or changing an infusion."]},"ethics":{"considerations":["Patients receiving it are critically ill and rely entirely on careful clinical judgement."],"affectedParties":["Critically ill patients","Families","Intensive care staff"]},"owners":{"steward":"The marketing authorisation holder where it is licensed; the treating clinician answers for each use.","roles":[],"masterSystems":["National medicines registers"]},"relations":[{"target":"Q11173","type":"parent","note":"registry parent class"}],"interaction":{"identity":{"applicability":"required","items":["Vercy registry: vr.tr.inamrinone","Wikidata: Q422724 (https://www.wikidata.org/wiki/Q422724)"]},"properties":{"applicability":"required","items":["Verified chemical identity: Source-verified structure, molecular formula, stereochemical specification where applicable, and chemical identifiers","Name equivalence: inamrinone ↔ amrinone, with authority, date and identity evidence","Material form: Parent substance, specified salt, solid form or solution; counterion and solvent where present","Assay and reporting basis: % mass fraction or mg/g; as received, dry basis or parent-equivalent basis","Impurity profile: Identified and unidentified impurities in %, ppm or mg/g, with method and detection limits","Solubility under specified conditions: mg/mL or mol/L, with solvent, pH, temperature and material form","Stability state: Within evidenced limits, suspected degradation, failed specification or unknown","Pharmacological evidence: Target or functional effect linked to assay, concentration, experimental system and source","Use qualification: Qualified for a specified use, restricted, rejected or not assessed"]},"recognition":{"applicability":"required","items":["A solution for intravenous use; identity is confirmed by label and pharmacy records, not appearance."]},"capabilities":{"applicability":"required","items":["Reconcile inamrinone and amrinone records using verified chemical identity evidence.","Compare a sample's analytical results with a specification appropriate to its stated form and use.","Translate concentration or assay results onto a parent-equivalent basis when composition is established.","Assess whether proposed dissolution and storage conditions have supporting evidence.","Flag ambiguous identity, precipitation, degradation or missing qualification for further investigation.","Link substance evidence to a separate medicinal-product or research model without transferring unsupported claims."]},"hazards":{"applicability":"required","items":["Can cause a fall in platelet count.","Arrhythmias and low blood pressure can occur.","Long-term use of this drug class was linked to higher mortality."]},"interfaces":{"applicability":"required","items":["The World Health Organization Anatomical Therapeutic Chemical classification assigns inamrinone code C01CE01 within phosphodiesterase inhibitors."]},"context":{"applicability":"required","items":["Inamrinone is encountered in pharmaceutical references and specialist hospital care as an intravenous medicine for short-term management of heart failure.","It is also used in pharmacological research on phosphodiesterase inhibition, cardiac contraction and vascular relaxation."]}},"sources":[{"title":"Wikidata item Q422724: inamrinone","url":"https://www.wikidata.org/wiki/Q422724","note":"identity and sense of the item"},{"title":"Wikipedia: Amrinone","url":"https://en.wikipedia.org/wiki/Amrinone","note":"general description of the item"}],"openQuestions":["Which authoritative records settle the parent structure, chemical identifiers and naming relationship between inamrinone and amrinone?","Which salts and solid forms are experimentally characterised, and which reported physical constants actually belong to those forms?","Which current analytical specifications identify relevant impurities and establish qualification for different intended uses?","What primary evidence establishes pH-dependent solubility, precipitation and degradation limits for the parent substance and relevant solutions?","Which current hazard classifications, exposure limits and jurisdiction-specific restrictions apply to inamrinone material rather than to a finished medicinal product?"],"resources":{"spec":"/models/things/publications/thing-q422724/spec.json"},"provenance":{"origin":"thing registry research (pass 2)","builtFrom":["models/things/publications/thing-q422724/spec.json"],"providers":["Codex"],"researchStatus":"unreviewed","generatedAt":"2026-09-12T10:26:57Z","builder":"tools/build_cards.py@1.0.0"},"completeness":{"sections":{"classifiers":"filled","whatItIs":"filled","purpose":"filled","distinguishingFeatures":"filled","structure":"filled","agentConduct":"filled","ethics":"filled","owners":"filled","relations":"filled","interaction.identity":"filled","interaction.properties":"filled","interaction.recognition":"filled","interaction.capabilities":"filled","interaction.hazards":"filled","interaction.interfaces":"filled","interaction.context":"filled","sources":"filled"},"notes":{"_gate":"Published through the thing publication gate 1.0 on 2026-10-07T10:10:30+00:00: completeness 1.00; sense: Wikidata description; 2 live sources; review by codex: pass"},"score":1.0}}